Eisler Capital Management Ltd. Acquires Shares of 136,360 Surmodics, Inc. (NASDAQ:SRDX)

Eisler Capital Management Ltd. purchased a new stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 136,360 shares of the company's stock, valued at approximately $5,394,000. Eisler Capital Management Ltd. owned about 0.95% of Surmodics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Deutsche Bank AG boosted its stake in shares of Surmodics by 77.8% during the 4th quarter. Deutsche Bank AG now owns 42,683 shares of the company's stock worth $1,690,000 after acquiring an additional 18,671 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its stake in shares of Surmodics by 40.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 125,927 shares of the company's stock worth $4,987,000 after acquiring an additional 36,429 shares in the last quarter. DeepCurrents Investment Group LLC purchased a new stake in shares of Surmodics during the 4th quarter worth about $260,000. Balyasny Asset Management L.P. purchased a new stake in shares of Surmodics during the 4th quarter worth about $4,921,000. Finally, Bank of America Corp DE boosted its stake in shares of Surmodics by 15.8% during the 4th quarter. Bank of America Corp DE now owns 24,613 shares of the company's stock worth $975,000 after acquiring an additional 3,351 shares in the last quarter. 96.63% of the stock is owned by hedge funds and other institutional investors.

Surmodics Trading Up 1.2%

Shares of NASDAQ SRDX traded up $0.33 during midday trading on Monday, reaching $27.09. 49,277 shares of the stock were exchanged, compared to its average volume of 277,470. Surmodics, Inc. has a twelve month low of $26.00 and a twelve month high of $42.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The company has a 50 day simple moving average of $28.79 and a 200 day simple moving average of $34.40. The stock has a market capitalization of $387.36 million, a P/E ratio of -26.82 and a beta of 1.32.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). The business had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. As a group, equities analysts expect that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on SRDX shares. StockNews.com started coverage on shares of Surmodics in a research note on Monday, February 3rd. They issued a "hold" rating on the stock. Lake Street Capital upgraded shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective for the company in a report on Friday, March 7th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Surmodics has a consensus rating of "Hold" and a consensus target price of $43.00.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).